Related Experiment Videos
Perspectives on the future of chronic myeloid leukemia treatment
1Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109-1024, USA.
Abstract:
Chronic myeloid leukemia (CML) is probably the best understood human malignancy at the molecular level, but among the hardest to explain to patients concerning appropriate treatment options. At present, we do not know the long-term outcome of promising new therapies such as the tyrosine kinase inhibitor imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ) (formerly STI571) and nonmyeloablative transplants. There is also no reliable way to predict which patients will respond to a particular therapy. The development of methods to predict therapeutic response will be of major benefit to patients, and the newly emerging science of gene array analysis may provide such a tool. In this context, given the proven likelihood of cure with allogeneic transplantation and the negative effects of delay, in Seattle we continue to suggest transplantation as the initial form of therapy for patients below age 55 years with matched sibling donors. For patients without matched donors below the age of 40, we would suggest an unrelated donor search and only proceed directly to transplant for those with allele-level matches. For younger patients without matches and those aged 40 to 55, an initial trial of imatinib mesylate might be preferred. For patients over age 55 with CML, initial therapy with imatinib mesylate, possibly an interferon-containing regimen or nonmyeloablative allogeneic transplantation may be considered.
Insights
Predicting treatment response in chronic myeloid leukemia (CML) is crucial. Gene array analysis may offer a tool to personalize therapy, guiding decisions between imatinib mesylate and transplantation for CML patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myeloid leukemia (CML) is a well-understood molecular malignancy.
- Current treatment options, including imatinib mesylate and nonmyeloablative transplants, have uncertain long-term outcomes.
- Predicting individual patient response to specific therapies remains a challenge.
Purpose of the Study:
- To explore the potential of gene array analysis for predicting therapeutic response in CML.
- To provide guidance on selecting appropriate initial therapies for CML patients based on age and donor availability.
Main Methods:
- Review of current CML treatment strategies.
- Consideration of emerging gene array analysis techniques.
- Clinical decision-making framework based on patient age, donor match status, and treatment options.
Main Results:
- Allogeneic transplantation offers a proven cure for CML, particularly for younger patients with matched sibling donors.
- For patients lacking matched donors, an unrelated donor search is recommended.
- Imatinib mesylate is a preferred initial therapy for younger patients without matches and those aged 40-55.
- For patients over 55, imatinib mesylate, interferon-based regimens, or nonmyeloablative allogeneic transplantation are considered.
Conclusions:
- Personalized treatment strategies are essential for optimizing CML patient outcomes.
- Gene array analysis holds promise for predicting treatment response and tailoring therapy.
- Treatment decisions should balance the curative potential of transplantation with the risks and benefits of imatinib mesylate and other therapies.